Merck completes $10 billion acquisition of Verona Pharma, adds COPD drug Ohtuvayre
Merck & Co. Inc. (NYSE:MRK) is one of the The best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:RNAV). Verona Pharma is now a wholly owned subsidiary of Merck. The acquisition is valued at approximately $10 billion and was executed under the…